COVID-19 Related Products

SARS-CoV-2-IN-32 is a potent inhibitor targeting the main protease (Mpro) of SARS-CoV-2, demonstrating a high binding affinity of -8.8 Kcal/mole. This compound exhibits anti-proliferative activity against cancer cells, making it suitable for dual research applications in the fields of oncology and virology. SARS-CoV-2-IN-32 can be utilized in studies focused on the treatment of COVID-19 and cancer therapies.

Hispidulin 4'-O-β-D-glucopyranoside acts as an inhibitor of the COVID-19 main protease. This natural compound demonstrates significant potential for antiviral activity, specifically against SARS-CoV-2. It is of interest for research focused on therapeutic strategies for COVID-19 treatment and prevention.

SARS-CoV-2-IN-31 is an inhibitor targeting SARS-CoV-2 viral replication. This compound demonstrates notable biological activity against various cancer cell lines, with IC50 values ranging from 28.84 to 38.36 μM. It serves as a valuable tool for research into both COVID-19 and cancer therapeutic applications.

SARS-CoV-2-IN-33 is an inhibitor targeting the SARS-CoV-2 main protease (Mpro). This compound demonstrates significant anti-proliferative activity against cancer cells, making it relevant for research in both COVID-19 and cancer biology. With a binding affinity of -8.0 kcal/mol to the Mpro (PDB ID: 6LU7), SARS-CoV-2-IN-33 serves as a valuable tool for investigating therapeutic strategies against COVID-19 and exploring potential cancer treatment applications.

RBT-9 is a COVID-19 inhibitor that targets viral replication and inflammation pathways. It has demonstrated efficacy in preventing the progression to severe COVID-19 and associated organ failure. Furthermore, RBT-9 exhibits antiviral activity against various enveloped viruses, including influenza, hepatitis C virus (HCV), dengue, and yellow fever, making it a valuable tool for research in viral pathogenesis and therapeutic intervention.